Life Sciences
Market Access, HTA & Reimbursement Strategy
Zinergy provides senior expertise in Market Access, HTA and reimbursement, with a focus on AMNOG and the evolving European HTA environment.
We combine strategic advice with hands-on project delivery, including evidence assessments, medical writing and independent scientific review for defined HTA and reimbursement work packages.
From Evidence to Access
Successful Market Access requires a clear understanding of how evidence will be assessed and translated into reimbursement decisions.
We translate HTA requirements into practical recommendations and scientific deliverables – from early scoping and the preparation of G-BA consultation requests and supporting documents to the drafting and revision of individual AMNOG dossier sections.
Who We Support
We work with pharmaceutical and biotechnology companies seeking experienced external expertise for defined Market Access, HTA and reimbursement projects.
Market Access Strategy
We address Market Access considerations early and link them to expected HTA and reimbursement requirements.
Our Services Include:
Early HTA and reimbursement considerations
HTA landscape and precedent assessments
Strategic input into evidence and access planning
Identification of key access risks and decision points
AMNOG and EU HTA
We support clients with strategic advice and practical delivery across key HTA milestones, focusing on AMNOG in Germany and providing complementary support on EU HTA requirements.
Our Services Include:
AMNOG and HTA scoping and strategy
Research on appropriate comparators, endpoints, clinical guidelines and HTA precedents
Evidence assessments and scientific reports
Consultations: concept, preparation of requests and supporting documents, training and participation
Medical writing: drafting and revision of individual dossier sections
Independent scientific review and quality assurance
Strategic support on HTA requirements
Senior Advisory and Project Leadership
We step in where complex Market Access and HTA questions require experienced judgment, focused execution and clear strategic direction.
Our Services Include:
Leadership of defined Market Access and HTA projects and workstreams
Independent review and challenge of strategies, evidence packages and key deliverables
Strategic input at critical decision points
Additional senior capacity during critical project phases
Practice Leadership
Dr. Elke Ziegler
Director, Life Sciences
Market Access, HTA & Reimbursement Strategy
Dr. Elke Ziegler leads Zinergy’s Life Sciences practice and advises pharmaceutical and biotechnology organisations on Market Access, HTA, reimbursement and evidence strategy in Germany and Europe.
She works directly with clients on defined projects and workstreams, providing senior strategic and analytical input on complex Market Access and HTA questions alongside hands-on support in evidence assessment, medical writing and independent scientific review. Her experience spans the pharmaceutical industry, the G-BA (Germany’s Federal Joint Committee) and consulting, giving her a broad perspective on assessment requirements and decision-making processes. This enables her to assess complex requirements, challenge strategic assumptions and translate evidence and HTA requirements into clear, decision-relevant recommendations and scientific deliverables.
Discuss Your Market Access Challenge
Whether you are preparing for an HTA milestone, addressing a complex evidence question or looking for strategic advice and hands-on support on a defined project, we provide focused senior expertise tailored to your situation.